Yousif Capital Management LLC Lowers Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Yousif Capital Management LLC lowered its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,077 shares of the biotechnology company’s stock after selling 667 shares during the quarter. Yousif Capital Management LLC’s holdings in ADMA Biologics were worth $1,562,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Creative Planning increased its holdings in ADMA Biologics by 73.9% in the 2nd quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 15,363 shares during the last quarter. CWM LLC grew its position in shares of ADMA Biologics by 72.5% during the third quarter. CWM LLC now owns 14,129 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 5,937 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 888 shares in the last quarter. Inspire Advisors LLC bought a new stake in shares of ADMA Biologics in the third quarter worth about $417,000. Finally, Veracity Capital LLC purchased a new stake in shares of ADMA Biologics in the third quarter worth about $427,000. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Down 0.3 %

Shares of NASDAQ:ADMA opened at $15.84 on Thursday. The company has a market cap of $3.74 billion, a price-to-earnings ratio of 56.57 and a beta of 0.75. ADMA Biologics, Inc. has a 12 month low of $5.02 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $17.50 and a 200 day moving average price of $17.77.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.